ストックスクリーナーアプリを入手
20.24
6.38%
-1.38
プレマーケット:
20.95
0.71
+3.51%
Tango Therapeutics Inc (TNGX) 最新ニュース
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
A Look At Tango Therapeutics (TNGX) Valuation After Wider Losses And Boardroom Changes - Yahoo Finance
Tango Therapeutics is the best performing healthcare stock in March - MSN
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Why Tango Therapeutics (TNGX) Is Down 12.4% After Gilead Exit, Wider Loss And Board ChangesAnd What's Next - Sahm
TNGX stock crashes 20% after reporting $0 revenue in Q1 — but analysts still see massive upside - MSN
Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board ChangesHas The Bull Case Changed? - Yahoo Finance
Tango Therapeutics (TNGX) Experiences Significant Decline - GuruFocus
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
[SCHEDULE 13G/A] Tango Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Nextech Crossover reports 7.27M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Jefferies downgrades Tango Therapeutics (TNGX) - MSN
Mizuho Raises Price Target on Tango Therapeutics to $30 From $20, Keeps Outperform Rating - Moomoo
TNGX Maintained by Mizuho -- Price Target Raised to $30 - GuruFocus
Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Tango Therapeutics Shares Fall After Jefferies Downgrade - Moomoo
Mizuho Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Woodline Partners reports 8.0M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Tango Therapeutics Price Target Raised to $30.00/Share From $20.00 by Mizuho - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $55 - Moomoo
RTW Funds disclose 13.3M shares in Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift By Investing.com - Investing.com Australia
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift - Investing.com UK
Piper Sandler downgrades Tango Therapeutics (TNGX) - MSN
TNGX Downgraded by Jefferies -- Price Target Raised to $27 - GuruFocus
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Mizuho raises Tango Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Nigeria
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $30.1, Implies 18% Upside - TradingView
Mizuho raises Tango Therapeutics stock price target on pipeline progress - Investing.com
Tango Therapeutics price target raised to $33 from $19 at Wedbush - TipRanks
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27.4, Implies 7% Upside - TradingView
Tango Therapeutics Is Maintained at Outperform by Wedbush - Moomoo
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Wedbush Adjusts Price Target on Tango Therapeutics to $33 From $19, Maintains Outperform Rating - Moomoo
Tango Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies downgrades Tango Therapeutics stock rating on valuation - Investing.com
Jefferies downgrades Tango Therapeutics stock rating on valuation By Investing.com - Investing.com Australia
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $24.8, Implies 3% Downside - TradingView
Tango Therapeutics (TNGX) Zero Q1 Revenue Tests Bullish 56.6% Growth Narrative - Sahm
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):